Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted): 2011-2024

Historic EPS (Weighted Average and Diluted) for Ptc Therapeutics (PTCT) over the last 10 years, with Dec 2024 value amounting to -$4.73.

  • Ptc Therapeutics' EPS (Weighted Average and Diluted) rose 114.39% to $0.20 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.56, marking a year-over-year increase of 244.11%. This contributed to the annual value of -$4.73 for FY2024, which is 43.49% up from last year.
  • Per Ptc Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$4.73 for FY2024, which was up 43.49% from -$8.37 recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$4.73 in FY2024 and a low of -$8.37 during FY2023.
  • Over the past 3 years, Ptc Therapeutics' median EPS (Weighted Average and Diluted) value was -$7.79 (recorded in 2022), while the average stood at -$6.96.
  • As far as peak fluctuations go, Ptc Therapeutics' EPS (Weighted Average and Diluted) tumbled by 55.50% in 2020, and later spiked by 43.49% in 2024.
  • Over the past 5 years, Ptc Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$6.64 in 2020, then dropped by 11.90% to -$7.43 in 2021, then decreased by 4.85% to -$7.79 in 2022, then fell by 7.45% to -$8.37 in 2023, then spiked by 43.49% to -$4.73 in 2024.